Literature DB >> 17698904

Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome.

Sophie Catteau-Jonard1, Pascal Pigny, Anne-Céline Reyss, Christine Decanter, Edouard Poncelet, Didier Dewailly.   

Abstract

CONTEXT: We previously hypothesized that the excess of anti-müllerian hormone (AMH) at the level of selectable follicles could be involved in the follicular arrest of polycystic ovary syndrome (PCOS), mainly through inhibition of FSH effect on aromatase expression.
OBJECTIVE: In this study, we investigated whether a decrease in the serum AMH level was concomitant to the appearance of a dominant follicle induced by administration of mild amounts of exogenous FSH in women with PCOS.
DESIGN: A total of 30 women with PCOS in whom anovulation was resistant to clomiphene citrate received recombinant FSH using the low-dose step-up protocol during only one cycle. Serum levels of estradiol, AMH, LH, FSH, inhibin B, and ultrasound parameters were assessed twice a week until 3 d after the appearance of one or more dominant follicle(s).
RESULTS: The day of dominance (d 0) was defined by the appearance of at least one follicle more than 10 mm growing 2 mm/d. From d -14 before dominance to d +3, the mean serum AMH level and the 2- to 5-mm follicle number at ultrasound declined steadily, although not significantly by ANOVA. Mean AMH relative values (100% being the value at d 0) declined significantly (P = 0.04), from 125 +/- 32% at d -14 to 105 +/- 15% at d -4. Within the same time lag, the mean FSH relative values increased from 91 +/- 17% to 107 +/- 19% (P = 0.013). In the 87 samples obtained from d -14 to -4, absolute values of AMH were positively and negatively associated with those of LH and FSH, respectively, in an independent manner (P = 0.009 and P = 0.03, respectively). In the 55 samples collected at d 0 and +3, they were negatively correlated to those of estradiol (r = -0.272; P < 0.05).
CONCLUSIONS: These data suggest that in anovulatory women with PCOS, gently increasing the serum FSH level reduces the AMH excess, thus relieving the inhibition from the latter on aromatase expression by selectable follicles and allowing the emergence of a dominant follicle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698904     DOI: 10.1210/jc.2007-0868

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  18 in total

1.  New perspectives on the role of anti-Müllerian hormone (AMH) in women.

Authors:  Renato Pasquali
Journal:  Ann Transl Med       Date:  2018-12

Review 2.  Emerging Roles of Anti-Müllerian Hormone in Hypothalamic-Pituitary Function.

Authors:  Anne-Laure Barbotin; Maëliss Peigné; Samuel Andrew Malone; Paolo Giacobini
Journal:  Neuroendocrinology       Date:  2019-07-05       Impact factor: 4.914

3.  Serum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism.

Authors:  Alice S Park; Mark A Lawson; Sandy S Chuan; Sharon E Oberfield; Kathleen M Hoeger; Selma F Witchel; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2010-02-11       Impact factor: 5.958

4.  Serum and follicular anti-Mullerian hormone levels in women with polycystic ovary syndrome (PCOS) under metformin.

Authors:  Angela Falbo; Morena Rocca; Tiziana Russo; Antonietta D'Ettore; Achille Tolino; Fulvio Zullo; Francesco Orio; Stefano Palomba
Journal:  J Ovarian Res       Date:  2010-07-21       Impact factor: 4.234

Review 5.  Is AMH a regulator of follicular atresia?

Authors:  David B Seifer; Zaher Merhi
Journal:  J Assist Reprod Genet       Date:  2014-09-06       Impact factor: 3.412

6.  Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys.

Authors:  D A Dumesic; M S Patankar; D K Barnett; T G Lesnick; B A Hutcherson; D H Abbott
Journal:  Hum Reprod       Date:  2009-09-09       Impact factor: 6.918

7.  Lack of Serum anti-Mullerian hormone responses after recombinant human chorionic gonadotropin stimulation in women with polycystic ovary syndrome.

Authors:  Heidi Cook-Andersen; Sandy S Chuan; Kevin Maas; Marcus A Rosencrantz; H Irene Su; Mark Lawson; Helen D Mason; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

8.  The association of parity and breastfeeding with anti-Müllerian hormone levels at two time points.

Authors:  Nydjie P Grimes; Brian W Whitcomb; Katherine W Reeves; Lynnette L Sievert; Alexandra Purdue-Smithe; JoAnn E Manson; Susan E Hankinson; Bernard A Rosner; Elizabeth R Bertone-Johnson
Journal:  Maturitas       Date:  2021-09-20       Impact factor: 4.342

9.  High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.

Authors:  Yaxin Guo; Shuai Liu; Shiqiao Hu; Fei Li; Lei Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-26       Impact factor: 5.555

10.  Association between serum anti-Müllerian hormone level and ovarian response to mild stimulation in normoovulatory women and anovulatory women with polycystic ovary syndrome.

Authors:  Ju Yeong Kim; Gwang Yi; Yeo Rang Kim; Jae Yeon Chung; Ji Hyun Ahn; You Kyoung Uhm; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim
Journal:  Clin Exp Reprod Med       Date:  2013-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.